

# Product datasheet for TR502591

## Map2k4 Mouse shRNA Plasmid (Locus ID 26398)

### **Product data:**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product Type:	shRNA Plasmids
Product Name:	Map2k4 Mouse shRNA Plasmid (Locus ID 26398)
Locus ID:	26398
Synonyms:	JNKK1; MEK4; MKK4; PRKMK4; Sek1; Serk1
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	Map2k4 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 26398). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	<u>BC029833, NM 001316367, NM 001316368, NM 001316369, NM 009157, NM 009157.1, NM 009157.1, NM 009157.3, NM 009157.4, NM 009157.5, NM 001362739, NM 001362740</u>
UniProt ID:	<u>P47809</u>



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

#### ORIGENE Map2k4 Mouse shRNA Plasmid (Locus ID 26398) – TR502591

Summary:	Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK activation at least in response to proinflammatory cytokines, while other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylate JNKs. MAP2K4 is required for maintaining peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7 exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38 MAPKs MAPK11, MAPK12, MAPK13 and MAPX14.[UniProtKB/Swiss-Prot
	Function]

shRNA Design:These shRNA constructs were designed against multiple splice variants at this gene locus. To<br/>be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a>.If you need a special design or shRNA sequence, please utilize our <a href="mailto:custom shRNA service">custom shRNA service</a>.

PerformanceOriGene guarantees that the sequences in the shRNA expression cassettes are verified toGuaranteed:correspond to the target gene with 100% identity. One of the four constructs at minimum are<br/>guaranteed to produce 70% or more gene expression knock-down provided a minimum<br/>transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to<br/>evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly<br/>assess knockdown, the gene expression level from the included scramble control vector must<br/>be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US